Search

Your search keyword '"Lagrasta C."' showing total 17 results
Start Over Author "Lagrasta C." Search Limiters Peer Reviewed
17 results on '"Lagrasta C."'

5. Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?

Author

Prezioso, L., Tanzi, S., Galaverna, F., Frati, C., Testa, B., Savi, M., Graiani, G., Lagrasta, C., Cavalli, S., Galati, S., Madeddu, D., Rizzini, E. Lodi, Ferraro, F., Musso, E., Stilli, D., Urbanek, K., Piegari, E., De Angelis, A., Maseri, A., Rossi, F., Quaini, E., and Quaini, F.

Published
2010

8. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

Author

Bozzetti, C, Negri, F V, Lagrasta, C A, Crafa, P, Bassano, C, Tamagnini, I, Gardini, G, Nizzoli, R, Leonardi, F, Gasparro, D, Camisa, R, Capelli, S, Silini, E M, Ardizzoni, A, and Cavalli, S

Subjects
METASTASIS, GASTROINTESTINAL cancer, TRASTUZUMAB, HER2 gene, ADENOCARCINOMA, CANCER treatment, IMMUNOHISTOCHEMISTRY
Abstract

Background: Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma. Although antibody-based therapies target the metastatic disease, HER2 status is usually evaluated in the primary tumour because metastatic sites are rarely biopsied. The aim of this study was to compare HER2 status in primary and paired metastatic sites of gastric adenocarcinoma.Methods: The HER2 status was assessed by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in 72 secondary lesions of gastric adenocarcinoma and in the corresponding primary tumours.Results: Concordance of FISH results, evaluable in 68 primary and matched metastatic sites, was 98.5%. Concordance of IHC results, available in 39 of the 72 paired cases, was 94.9%. Only one case showed discordance between primary tumour and metastasis, being negative by both IHC and FISH in the primary and showing HER2 overexpression and amplification in the corresponding pancreatic lymph node metastasis.Conclusion: The high concordance observed between HER2 results obtained by both IHC and FISH on primary tumours and corresponding metastases suggests that in gastric cancer HER2 status is maintained in most cases unchanged during the metastatic process. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

9. PTEN status in advanced colorectal cancer treated with cetuximab.

Author

Negri, F. V., Bozzetti, C., Lagrasta, C. A., Crafa, P., Bonasoni, M. P., Camisa, R., Pedrazzi, G., and Ardizzoni, A.

Subjects
PHOSPHATASES, COLON cancer, CETUXIMAB, CHROMOSOME abnormalities, EPIDERMAL growth factor, GENETIC transduction, BONE metastasis
Abstract

Background: Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway.Methods: PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n=43) and on metastatic (n=24) sites in CRC patients treated with cetuximab.Results: The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; P<0.05), PFS (0.8 vs 8.2 months; P<0.001) and OS (2.9 vs 14.2 months; P<0.001).Conclusion: A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

12. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

Author

Vittorio Franciosi, Marzia Capelletti, Nicoletta Campanini, Guido Rindi, Alessandro Marchioni, Elena Spiritelli, Giulio Rossi, Cecilia Bozzetti, Roberta Camisa, Giuseppe De Palma, Costanza Lagrasta, Andrea Ardizzoni, Luca Boni, Giuliana Sartori, Marcello Tiseo, Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, and Ardizzoni A

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Receptor, ErbB-2, Gene Dosage, non-small cell lung cancer (NSCLC), Antineoplastic Agents, NSCLC Gefitinib EGFR gene mutation EGFR FISH EGFR gene polymorphism Biological predictive factors, Gene mutation, EGFR Gene Mutation, Gene dosage, Gefitinib, Carcinoma, Non-Small-Cell Lung, Internal medicine, Biomarkers, Tumor, medicine, Carcinoma, Humans, Prospective Studies, Epidermal growth factor receptor, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Polymorphism, Genetic, biology, business.industry, Cancer, Middle Aged, Prognosis, medicine.disease, Introns, respiratory tract diseases, ErbB Receptors, Treatment Outcome, Immunology, Quinazolines, biology.protein, Female, business, medicine.drug
Abstract

A number of different clinical characteristics and molecular markers related to epidermal growth factor receptor (EGFR) activation have been reported to singly correlate with therapeutic activity of EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). This study was designed to evaluate the predictive value on gefitinib outcomes of a comprehensive panel of molecular parameters in advanced NSCLC patients EGFR and K-ras mutations were detected by direct sequencing on tumor DNA from paraffin embedded samples EGFR and HER2 gene copy number was assessed by FISH EGFR protein expression was quantified by immunohistochemistry. EGFR gene intron 1 polymorphism was assessed on genomic DNA isolated from venous whole blood samples Ninety-one patients were prospectively enrolled and the overall gefitinib response rate was 18 7% (2 complete and 15 partial responses) Sex (p = 0005), non-smoking status (p = 0010). skin toxicity (p = 0020). EGFR gene mutations (p

Published
2010
Full Text
View/download PDF

13. 2O Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC.

Author

Mazzaschi, G, Quaini, F, Milanese, G, Madeddu, D, Bocchialini, G, Ampollini, L, Gnetti, L, Lagrasta, C, Silva, M, Roti, G, Sverzellati, N, and Tiseo, M

Subjects
*ACADEMIC medical centers, *NON-small-cell lung carcinoma, *TUMORS, *BONE marrow transplantation, *UNIVERSITY hospitals
Published
2019
Full Text
View/download PDF

14. Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non-small Cell Lung Cancer?

Author

Rita Nizzoli, Guido Rindi, Andrea Ardizzoni, Gallia Graiani, Cecilia Bozzetti, Costanza Lagrasta, Annamaria Guazzi, Marcello Tiseo, Bozzetti C, Tiseo M, Lagrasta C, Nizzoli R, Guazzi A, Graiani G, Rindi G, and Ardizzoni A

Subjects
Pulmonary and Respiratory Medicine, Pathology, medicine.medical_specialty, Lung Neoplasms, EGFR, Cell, Gene Dosage, Adenocarcinoma, Biology, NSCLC, FISH, Carcinoma, Non-Small-Cell Lung, Cytology, medicine, Humans, Copy-number variation, Epidermal growth factor receptor, NSCLC, EGFR, FISH, Cytology, Lung cancer, Gene, In Situ Hybridization, Fluorescence, Neoplasm Staging, Lung, integumentary system, medicine.diagnostic_test, Prognosis, medicine.disease, ErbB Receptors, Survival Rate, medicine.anatomical_structure, Oncology, Carcinoma, Squamous Cell, Cancer research, biology.protein, Feasibility Studies, Fluorescence in situ hybridization
Abstract

Background Epidermal growth factor receptor (EGFR) gene copy number has been proposed as predictor of response to epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer (NSCLC). Methods Cytologic and matched histologic samples from 33 primary non-small cell lung cancers were analyzed by fluorescence in situ hybridization (FISH) for epidermal growth factor receptor gene. Results FISH was positive in 52% and negative in 35% of the 31 matched evaluable samples. Four of 31 (13%) cases were discordant ( K = 0.736; p Conclusion Our data support the feasibility and reliability of epidermal growth factor receptor gene assessment by FISH on cytology.

Published
2010
Full Text
View/download PDF

16. In vitro biological and functional properties of human endothelial cells from different sources exposed to different beta-blockers.

Author

Lorusso, B., Madeddu, D., Falco, A., Gervasi, A., Frati, C., Manni, S., Rinaldi, L., Nannetti, A., Spigoni, V., Pilato, F.P., Gnetti, L., Lagrasta, C., Frusca, T., Cerasoli, G., and Quaini, F.

Subjects
*ADRENERGIC beta blockers, *CARDIOVASCULAR disease treatment, *ENDOTHELIAL cells, *CELL proliferation, *IN vitro studies, *ETIOLOGY of diseases
Published
2015
Full Text
View/download PDF

17. Assessment of cardiac patches suitability for tissue engineering.

Author

Madeddu, D., Falco, A., Frati, C., Graiani, G., Gervasi, A., Lorusso, B., Rosellini, E., Rai, R., Boccaccini, A.R., Lagrasta, C., and Quaini, F.

Subjects
*MYOCARDIUM, *HEART failure treatment, *TISSUE engineering, *HEART cells, *PROGENITOR cells, *DISEASE progression, *REGENERATIVE medicine
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results